These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 25589938)
1. Synthesis and Structure-Activity Relationship Study of 5a-Carbasugar Analogues of SL0101. Li M; Li Y; Mrozowski RM; Sandusky ZM; Shan M; Song X; Wu B; Zhang Q; Lannigan DA; O'Doherty GA ACS Med Chem Lett; 2015 Jan; 6(1):95-9. PubMed ID: 25589938 [TBL] [Abstract][Full Text] [Related]
2. Improving the affinity of SL0101 for RSK using structure-based design. Mrozowski RM; Vemula R; Wu B; Zhang Q; Schroeder BR; Hilinski MK; Clark DE; Hecht SM; O'Doherty GA; Lannigan DA ACS Med Chem Lett; 2012 Feb; 4(2):175-179. PubMed ID: 23519677 [TBL] [Abstract][Full Text] [Related]
3. Stereoselective Synthesis and Evaluation of C6″-Substituted 5a-Carbasugar Analogues of SL0101 as Inhibitors of RSK1/2. Li M; Li Y; Ludwik KA; Sandusky ZM; Lannigan DA; O'Doherty GA Org Lett; 2017 May; 19(9):2410-2413. PubMed ID: 28441024 [TBL] [Abstract][Full Text] [Related]
4. Synthesis of SL0101 carbasugar analogues: carbasugars via Pd-catalyzed cyclitolization and post-cyclitolization transformations. Shan M; O'Doherty GA Org Lett; 2010 Jul; 12(13):2986-9. PubMed ID: 20518547 [TBL] [Abstract][Full Text] [Related]
5. Structural basis for the activity of the RSK-specific inhibitor, SL0101. Smith JA; Maloney DJ; Hecht SM; Lannigan DA Bioorg Med Chem; 2007 Jul; 15(14):5018-34. PubMed ID: 17512736 [TBL] [Abstract][Full Text] [Related]
6. Influence of rhamnose substituents on the potency of SL0101, an inhibitor of the Ser/Thr kinase, RSK. Smith JA; Maloney DJ; Clark DE; Xu Y; Hecht SM; Lannigan DA Bioorg Med Chem; 2006 Sep; 14(17):6034-42. PubMed ID: 16723233 [TBL] [Abstract][Full Text] [Related]
7. Analogs of the RSK inhibitor SL0101: optimization of in vitro biological stability. Hilinski MK; Mrozowski RM; Clark DE; Lannigan DA Bioorg Med Chem Lett; 2012 May; 22(9):3244-7. PubMed ID: 22464132 [TBL] [Abstract][Full Text] [Related]
8. De novo synthesis and biological evaluation of C6″-substituted C4″-amide analogues of SL0101. Mrozowski RM; Sandusky ZM; Vemula R; Wu B; Zhang Q; Lannigan DA; O'Doherty GA Org Lett; 2014 Nov; 16(22):5996-9. PubMed ID: 25372628 [TBL] [Abstract][Full Text] [Related]
9. The affinity of RSK for cylitol analogues of SL0101 is critically dependent on the B-ring C-4'-hydroxy. Li Y; Seber P; Wright EB; Yasmin S; Lannigan DA; O'Doherty GA Chem Commun (Camb); 2020 Mar; 56(20):3058-3060. PubMed ID: 32048692 [TBL] [Abstract][Full Text] [Related]
10. Two widely used RSK inhibitors, BI-D1870 and SL0101, alter mTORC1 signaling in a RSK-independent manner. Roffé M; Lupinacci FC; Soares LC; Hajj GN; Martins VR Cell Signal; 2015 Aug; 27(8):1630-42. PubMed ID: 25889895 [TBL] [Abstract][Full Text] [Related]
11. Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. Smith JA; Poteet-Smith CE; Xu Y; Errington TM; Hecht SM; Lannigan DA Cancer Res; 2005 Feb; 65(3):1027-34. PubMed ID: 15705904 [TBL] [Abstract][Full Text] [Related]
12. Regioselective Synthesis of a Li Y; Sandusky ZM; Vemula R; Zhang Q; Wu B; Fukuda S; Li M; Lannigan DA; O'Doherty GA Org Lett; 2020 Feb; 22(4):1448-1452. PubMed ID: 32009414 [TBL] [Abstract][Full Text] [Related]
13. Insights into the inhibition of the p90 ribosomal S6 kinase (RSK) by the flavonol glycoside SL0101 from the 1.5 Å crystal structure of the N-terminal domain of RSK2 with bound inhibitor. Utepbergenov D; Derewenda U; Olekhnovich N; Szukalska G; Banerjee B; Hilinski MK; Lannigan DA; Stukenberg PT; Derewenda ZS Biochemistry; 2012 Aug; 51(33):6499-510. PubMed ID: 22846040 [TBL] [Abstract][Full Text] [Related]
14. Identifying requirements for RSK2 specific inhibitors. Wright EB; Fukuda S; Li M; Li Y; O'Doherty GA; Lannigan DA J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1798-1809. PubMed ID: 34348556 [TBL] [Abstract][Full Text] [Related]
15. Identification of quercitrin as an inhibitor of the p90 S6 ribosomal kinase (RSK): structure of its complex with the N-terminal domain of RSK2 at 1.8 Å resolution. Derewenda U; Artamonov M; Szukalska G; Utepbergenov D; Olekhnovich N; Parikh HI; Kellogg GE; Somlyo AV; Derewenda ZS Acta Crystallogr D Biol Crystallogr; 2013 Feb; 69(Pt 2):266-75. PubMed ID: 23385462 [TBL] [Abstract][Full Text] [Related]
16. The Clinical Implications of RSK1-3 in Human Breast Cancer. Zhao H; Martin TA; Davies EL; Ruge F; Yu H; Zhang Y; Teng XU; Jiang WG Anticancer Res; 2016 Mar; 36(3):1267-74. PubMed ID: 26977024 [TBL] [Abstract][Full Text] [Related]
17. Ribosomal S6 kinase (RSK) modulators: a patent review. Ludwik KA; Lannigan DA Expert Opin Ther Pat; 2016 Sep; 26(9):1061-78. PubMed ID: 27410995 [TBL] [Abstract][Full Text] [Related]
18. The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation. Clark DE; Errington TM; Smith JA; Frierson HF; Weber MJ; Lannigan DA Cancer Res; 2005 Apr; 65(8):3108-16. PubMed ID: 15833840 [TBL] [Abstract][Full Text] [Related]
19. De novo asymmetric syntheses of SL0101 and its analogues via a palladium-catalyzed glycosylation. Shan M; O'Doherty GA Org Lett; 2006 Oct; 8(22):5149-52. PubMed ID: 17048865 [TBL] [Abstract][Full Text] [Related]
20. Synthesis of a potent and selective inhibitor of p90 Rsk. Maloney DJ; Hecht SM Org Lett; 2005 Mar; 7(6):1097-9. PubMed ID: 15760148 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]